Mosoka Papa Fallah, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hemorrhagic Fever, Ebola | 58 | 2024 | 428 | 13.480 |
Why?
|
Ebolavirus | 21 | 2023 | 263 | 4.340 |
Why?
|
Liberia | 48 | 2023 | 167 | 3.820 |
Why?
|
Epidemics | 15 | 2024 | 523 | 3.410 |
Why?
|
Disease Outbreaks | 28 | 2024 | 1772 | 3.000 |
Why?
|
Survivors | 8 | 2021 | 2291 | 1.410 |
Why?
|
Ebola Vaccines | 3 | 2023 | 24 | 1.260 |
Why?
|
Contact Tracing | 7 | 2023 | 273 | 0.880 |
Why?
|
Africa | 9 | 2024 | 673 | 0.820 |
Why?
|
Financial Management | 1 | 2022 | 160 | 0.770 |
Why?
|
Dengue | 1 | 2024 | 256 | 0.750 |
Why?
|
Pregnancy Outcome | 2 | 2023 | 2795 | 0.710 |
Why?
|
Uveitis | 3 | 2021 | 375 | 0.710 |
Why?
|
Community Health Services | 4 | 2019 | 650 | 0.680 |
Why?
|
Cholera | 1 | 2024 | 785 | 0.590 |
Why?
|
Scabies | 3 | 2021 | 14 | 0.590 |
Why?
|
Social Stigma | 2 | 2021 | 701 | 0.560 |
Why?
|
Eye Diseases | 1 | 2021 | 669 | 0.510 |
Why?
|
Trust | 1 | 2019 | 505 | 0.510 |
Why?
|
Africa, Western | 6 | 2024 | 154 | 0.480 |
Why?
|
Malaria | 1 | 2024 | 1239 | 0.470 |
Why?
|
Anti-Retroviral Agents | 1 | 2022 | 1715 | 0.420 |
Why?
|
Urban Population | 2 | 2020 | 2021 | 0.390 |
Why?
|
Clinical Protocols | 1 | 2017 | 1462 | 0.380 |
Why?
|
Lassa virus | 2 | 2021 | 97 | 0.360 |
Why?
|
Pandemics | 5 | 2024 | 8388 | 0.350 |
Why?
|
Lassa Fever | 2 | 2021 | 97 | 0.350 |
Why?
|
Toll-Like Receptor 2 | 1 | 2011 | 354 | 0.330 |
Why?
|
Rural Population | 2 | 2020 | 2210 | 0.330 |
Why?
|
Neisseria meningitidis, Serogroup C | 2 | 2018 | 11 | 0.330 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3022 | 0.320 |
Why?
|
Meningitis, Meningococcal | 2 | 2018 | 43 | 0.320 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1177 | 0.320 |
Why?
|
Toll-Like Receptor 4 | 1 | 2011 | 565 | 0.310 |
Why?
|
Delivery of Health Care | 5 | 2021 | 5319 | 0.310 |
Why?
|
Semen | 3 | 2021 | 316 | 0.310 |
Why?
|
Vaccination | 6 | 2024 | 3278 | 0.300 |
Why?
|
Humans | 80 | 2024 | 744343 | 0.300 |
Why?
|
Population Surveillance | 2 | 2017 | 2616 | 0.290 |
Why?
|
Communicable Disease Control | 4 | 2021 | 857 | 0.280 |
Why?
|
Poverty | 3 | 2023 | 2660 | 0.280 |
Why?
|
Health Services Accessibility | 3 | 2022 | 5137 | 0.270 |
Why?
|
Spleen | 2 | 2014 | 2362 | 0.270 |
Why?
|
Developing Countries | 1 | 2018 | 2815 | 0.270 |
Why?
|
Pain | 1 | 2019 | 4986 | 0.230 |
Why?
|
Growth and Development | 1 | 2023 | 52 | 0.230 |
Why?
|
Filoviridae | 2 | 2019 | 16 | 0.220 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 2503 | 0.210 |
Why?
|
Logic | 1 | 2022 | 39 | 0.210 |
Why?
|
Longitudinal Studies | 4 | 2023 | 13989 | 0.210 |
Why?
|
Medicine, African Traditional | 1 | 2021 | 29 | 0.200 |
Why?
|
Antiparasitic Agents | 1 | 2021 | 41 | 0.200 |
Why?
|
Democratic Republic of the Congo | 2 | 2018 | 88 | 0.200 |
Why?
|
RNA, Viral | 3 | 2021 | 2902 | 0.200 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2011 | 2938 | 0.200 |
Why?
|
Color Vision Defects | 1 | 2021 | 28 | 0.190 |
Why?
|
Infant | 6 | 2023 | 35136 | 0.180 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2022 | 214 | 0.180 |
Why?
|
Mass Vaccination | 1 | 2021 | 105 | 0.180 |
Why?
|
Quarantine | 1 | 2022 | 170 | 0.180 |
Why?
|
Filoviridae Infections | 1 | 2019 | 6 | 0.180 |
Why?
|
HIV Infections | 3 | 2022 | 16718 | 0.170 |
Why?
|
Measles Vaccine | 1 | 2019 | 76 | 0.170 |
Why?
|
Public Health Administration | 1 | 2021 | 240 | 0.170 |
Why?
|
Emigration and Immigration | 2 | 2018 | 404 | 0.160 |
Why?
|
Climate Change | 1 | 2024 | 418 | 0.160 |
Why?
|
Thailand | 1 | 2019 | 296 | 0.160 |
Why?
|
Diagnostic Tests, Routine | 2 | 2022 | 783 | 0.160 |
Why?
|
Adolescent | 16 | 2021 | 85781 | 0.150 |
Why?
|
Uganda | 1 | 2022 | 1243 | 0.150 |
Why?
|
Immunoassay | 2 | 2019 | 752 | 0.150 |
Why?
|
Medical Tourism | 1 | 2018 | 57 | 0.150 |
Why?
|
Macrophages | 2 | 2014 | 5655 | 0.150 |
Why?
|
Emergencies | 1 | 2024 | 1170 | 0.150 |
Why?
|
Measles | 1 | 2019 | 168 | 0.150 |
Why?
|
Mobile Health Units | 1 | 2018 | 80 | 0.150 |
Why?
|
World Health Organization | 2 | 2021 | 1318 | 0.140 |
Why?
|
Female | 27 | 2023 | 380194 | 0.140 |
Why?
|
Health Communication | 2 | 2017 | 214 | 0.140 |
Why?
|
Macular Edema | 1 | 2021 | 359 | 0.140 |
Why?
|
South Africa | 1 | 2022 | 1731 | 0.140 |
Why?
|
Immunization Programs | 1 | 2019 | 260 | 0.140 |
Why?
|
Adult | 20 | 2021 | 214055 | 0.140 |
Why?
|
Public Health | 4 | 2024 | 2603 | 0.140 |
Why?
|
International Agencies | 1 | 2017 | 240 | 0.140 |
Why?
|
Culture | 1 | 2020 | 633 | 0.140 |
Why?
|
Cytokines | 1 | 2011 | 7322 | 0.140 |
Why?
|
Memory Disorders | 2 | 2022 | 1184 | 0.130 |
Why?
|
Fatigue | 2 | 2022 | 1531 | 0.130 |
Why?
|
Models, Statistical | 3 | 2022 | 5102 | 0.130 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2018 | 253 | 0.130 |
Why?
|
Residence Characteristics | 2 | 2015 | 2050 | 0.130 |
Why?
|
Disaster Planning | 1 | 2021 | 549 | 0.130 |
Why?
|
Cicatrix | 1 | 2021 | 764 | 0.130 |
Why?
|
Intraocular Pressure | 1 | 2021 | 1270 | 0.130 |
Why?
|
Financial Support | 1 | 2015 | 115 | 0.120 |
Why?
|
Pregnancy | 4 | 2023 | 29144 | 0.120 |
Why?
|
Stochastic Processes | 1 | 2015 | 344 | 0.120 |
Why?
|
Dogs | 1 | 2019 | 3912 | 0.120 |
Why?
|
Leishmania major | 1 | 2014 | 57 | 0.120 |
Why?
|
Child | 13 | 2020 | 77709 | 0.120 |
Why?
|
Placenta | 1 | 2023 | 1698 | 0.120 |
Why?
|
Guinea | 3 | 2018 | 41 | 0.120 |
Why?
|
Male | 23 | 2021 | 350118 | 0.120 |
Why?
|
Antiprotozoal Agents | 1 | 2014 | 86 | 0.120 |
Why?
|
Antibodies, Viral | 3 | 2019 | 3176 | 0.120 |
Why?
|
Meglumine | 1 | 2014 | 149 | 0.120 |
Why?
|
Health Resources | 1 | 2020 | 911 | 0.120 |
Why?
|
Stillbirth | 1 | 2016 | 346 | 0.120 |
Why?
|
Cohort Studies | 5 | 2023 | 40561 | 0.110 |
Why?
|
Young Adult | 12 | 2021 | 56430 | 0.110 |
Why?
|
Live Birth | 1 | 2016 | 512 | 0.110 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 2014 | 124 | 0.110 |
Why?
|
Resilience, Psychological | 1 | 2020 | 676 | 0.110 |
Why?
|
Antibodies, Neutralizing | 2 | 2019 | 1978 | 0.110 |
Why?
|
Vaccines | 1 | 2021 | 822 | 0.110 |
Why?
|
International Cooperation | 2 | 2017 | 1420 | 0.110 |
Why?
|
Viral Load | 2 | 2019 | 3299 | 0.110 |
Why?
|
Aging | 1 | 2011 | 8664 | 0.100 |
Why?
|
Asymptomatic Infections | 2 | 2023 | 128 | 0.100 |
Why?
|
Cost of Illness | 1 | 2021 | 1859 | 0.100 |
Why?
|
Models, Economic | 1 | 2015 | 713 | 0.100 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4560 | 0.100 |
Why?
|
Abortion, Spontaneous | 1 | 2016 | 544 | 0.100 |
Why?
|
Child, Preschool | 6 | 2020 | 41006 | 0.100 |
Why?
|
Pregnant Women | 1 | 2016 | 568 | 0.100 |
Why?
|
Headache | 1 | 2019 | 1226 | 0.100 |
Why?
|
Glycoproteins | 1 | 2019 | 2263 | 0.090 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 25043 | 0.090 |
Why?
|
Infant, Newborn | 2 | 2023 | 25625 | 0.090 |
Why?
|
Organometallic Compounds | 1 | 2014 | 665 | 0.090 |
Why?
|
Genome, Viral | 3 | 2019 | 667 | 0.090 |
Why?
|
Models, Theoretical | 3 | 2020 | 3589 | 0.090 |
Why?
|
Health Facilities | 1 | 2015 | 573 | 0.090 |
Why?
|
Logistic Models | 3 | 2020 | 13408 | 0.090 |
Why?
|
Cluster Analysis | 4 | 2017 | 2715 | 0.080 |
Why?
|
Prenatal Care | 1 | 2016 | 1092 | 0.080 |
Why?
|
Middle Aged | 14 | 2021 | 213383 | 0.080 |
Why?
|
Tomography, Optical Coherence | 1 | 2021 | 2657 | 0.080 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2015 | 1381 | 0.080 |
Why?
|
Signal Transduction | 1 | 2011 | 23403 | 0.080 |
Why?
|
Infection Control | 1 | 2015 | 966 | 0.080 |
Why?
|
Mental Health | 1 | 2021 | 3019 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 1999 | 0.070 |
Why?
|
Qualitative Research | 3 | 2021 | 2682 | 0.070 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 1411 | 0.070 |
Why?
|
Odds Ratio | 1 | 2019 | 9849 | 0.070 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2015 | 1052 | 0.070 |
Why?
|
Incidence | 4 | 2021 | 20947 | 0.070 |
Why?
|
Vulnerable Populations | 2 | 2021 | 687 | 0.070 |
Why?
|
Mice, Inbred BALB C | 2 | 2014 | 6386 | 0.070 |
Why?
|
Streptococcus pneumoniae | 1 | 2011 | 714 | 0.070 |
Why?
|
Sierra Leone | 2 | 2016 | 166 | 0.070 |
Why?
|
Patient Isolation | 2 | 2016 | 100 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2017 | 3923 | 0.060 |
Why?
|
Health Policy | 1 | 2017 | 2661 | 0.060 |
Why?
|
Health Personnel | 4 | 2020 | 3218 | 0.060 |
Why?
|
Focus Groups | 2 | 2020 | 1321 | 0.060 |
Why?
|
Anthropology, Cultural | 1 | 2024 | 99 | 0.060 |
Why?
|
Communication | 3 | 2024 | 3749 | 0.060 |
Why?
|
Pilot Projects | 3 | 2023 | 8324 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2019 | 9274 | 0.050 |
Why?
|
Ivermectin | 1 | 2021 | 42 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 3870 | 0.050 |
Why?
|
Impetigo | 1 | 2020 | 8 | 0.050 |
Why?
|
Tropical Medicine | 1 | 2021 | 49 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 21746 | 0.050 |
Why?
|
Neglected Diseases | 1 | 2021 | 64 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14722 | 0.050 |
Why?
|
Aged | 6 | 2019 | 163280 | 0.050 |
Why?
|
History, 21st Century | 2 | 2017 | 1534 | 0.050 |
Why?
|
Dermoscopy | 1 | 2020 | 56 | 0.050 |
Why?
|
N-Acetylglucosaminyltransferases | 1 | 2021 | 171 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2011 | 5524 | 0.050 |
Why?
|
Prevalence | 3 | 2021 | 15226 | 0.050 |
Why?
|
Community Health Planning | 1 | 2020 | 165 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8089 | 0.040 |
Why?
|
Government Programs | 1 | 2021 | 275 | 0.040 |
Why?
|
Capacity Building | 1 | 2021 | 248 | 0.040 |
Why?
|
Antibodies, Blocking | 1 | 2019 | 253 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2022 | 1005 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 53288 | 0.040 |
Why?
|
Multilocus Sequence Typing | 1 | 2018 | 100 | 0.040 |
Why?
|
Risk Factors | 4 | 2018 | 72290 | 0.040 |
Why?
|
Nigeria | 1 | 2021 | 733 | 0.040 |
Why?
|
Vero Cells | 1 | 2019 | 485 | 0.040 |
Why?
|
Anticonvulsants | 1 | 2008 | 1916 | 0.040 |
Why?
|
Time Factors | 2 | 2017 | 40075 | 0.040 |
Why?
|
Behavior Therapy | 1 | 2024 | 865 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2019 | 401 | 0.040 |
Why?
|
Arthralgia | 1 | 2022 | 456 | 0.040 |
Why?
|
Receptors, Virus | 1 | 2021 | 648 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2018 | 57776 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2011 | 4665 | 0.040 |
Why?
|
Multiple Myeloma | 1 | 2015 | 5181 | 0.040 |
Why?
|
Neutralization Tests | 1 | 2019 | 758 | 0.040 |
Why?
|
Microspheres | 1 | 2019 | 777 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2018 | 468 | 0.030 |
Why?
|
Attitude | 1 | 2021 | 776 | 0.030 |
Why?
|
Limit of Detection | 1 | 2017 | 265 | 0.030 |
Why?
|
United States | 1 | 2024 | 69872 | 0.030 |
Why?
|
Occupational Exposure | 2 | 2017 | 1796 | 0.030 |
Why?
|
Serologic Tests | 1 | 2018 | 374 | 0.030 |
Why?
|
Probability | 1 | 2021 | 2505 | 0.030 |
Why?
|
Case Management | 1 | 2018 | 286 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 6773 | 0.030 |
Why?
|
Metagenomics | 1 | 2018 | 428 | 0.030 |
Why?
|
Community-Based Participatory Research | 1 | 2017 | 214 | 0.030 |
Why?
|
Immunization | 1 | 2019 | 1256 | 0.030 |
Why?
|
Genotype | 2 | 2019 | 12951 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10252 | 0.030 |
Why?
|
Mass Media | 1 | 2017 | 305 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2011 | 11483 | 0.030 |
Why?
|
Laboratories | 1 | 2017 | 463 | 0.030 |
Why?
|
Educational Status | 1 | 2021 | 2540 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2020 | 2539 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2023 | 5078 | 0.030 |
Why?
|
Research | 1 | 2021 | 1999 | 0.030 |
Why?
|
Animals | 5 | 2019 | 168757 | 0.030 |
Why?
|
Models, Psychological | 1 | 2017 | 811 | 0.030 |
Why?
|
Epilepsy | 1 | 2008 | 3310 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11124 | 0.030 |
Why?
|
Sweden | 1 | 2015 | 1345 | 0.030 |
Why?
|
Demography | 1 | 2017 | 1656 | 0.030 |
Why?
|
Administration, Topical | 1 | 2014 | 690 | 0.030 |
Why?
|
Viral Vaccines | 1 | 2018 | 636 | 0.030 |
Why?
|
Disease Progression | 2 | 2022 | 13284 | 0.030 |
Why?
|
Phylogeny | 1 | 2019 | 2803 | 0.030 |
Why?
|
Plasma Cells | 1 | 2015 | 591 | 0.030 |
Why?
|
Community-Acquired Infections | 1 | 2016 | 465 | 0.030 |
Why?
|
Sex Distribution | 1 | 2017 | 2297 | 0.030 |
Why?
|
Age Distribution | 1 | 2017 | 2902 | 0.020 |
Why?
|
Morbidity | 1 | 2016 | 1769 | 0.020 |
Why?
|
Maternal Health Services | 1 | 2016 | 455 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2021 | 4328 | 0.020 |
Why?
|
Liposomes | 1 | 2014 | 759 | 0.020 |
Why?
|
Health Services | 1 | 2015 | 758 | 0.020 |
Why?
|
Random Allocation | 1 | 2014 | 2429 | 0.020 |
Why?
|
Licensure, Pharmacy | 1 | 2008 | 2 | 0.020 |
Why?
|
Nipecotic Acids | 1 | 2008 | 38 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 20822 | 0.020 |
Why?
|
Piracetam | 1 | 2008 | 87 | 0.020 |
Why?
|
Mice | 2 | 2014 | 81183 | 0.020 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2008 | 141 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8340 | 0.020 |
Why?
|
Half-Life | 1 | 2008 | 661 | 0.020 |
Why?
|
Finland | 1 | 2008 | 602 | 0.020 |
Why?
|
Amines | 1 | 2008 | 276 | 0.020 |
Why?
|
Cross Infection | 1 | 2016 | 1416 | 0.020 |
Why?
|
Fructose | 1 | 2008 | 288 | 0.020 |
Why?
|
Triazines | 1 | 2008 | 315 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6459 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2015 | 2703 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2459 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2864 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9687 | 0.020 |
Why?
|
Family | 1 | 2015 | 3147 | 0.020 |
Why?
|
Genomics | 1 | 2019 | 5720 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7785 | 0.010 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2008 | 1121 | 0.010 |
Why?
|
Risk Assessment | 1 | 2023 | 23338 | 0.010 |
Why?
|
Mass Screening | 1 | 2017 | 5255 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2016 | 77449 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 29063 | 0.010 |
Why?
|
Skin | 1 | 2014 | 4364 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39050 | 0.010 |
Why?
|
Cell Line | 1 | 2014 | 15997 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 12804 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 17446 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2008 | 63114 | 0.000 |
Why?
|